Волосатоклеточный лейкоз

1. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, 2008.
2. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). Ed. S.H. Swerdlow, E. Campo, N.L. Harris et al. 2017.
3. Falini B, Martelli MP, Tiacci E. BRAF V600E mutation in hairy cell leukemia: From bench to bedside. Blood 2016; 128 (15): 1918–27.
4. Tadmor T, Polliack A. Epidemiology and environmental risk in hairy cell leukemia. Best Practice and Research: Clinical Haematology. Bailliere Tindall Ltd 2015; 28 (4): 175–9.
5. Аль-Ради Л.С. Волосатоклеточный лейкоз. В кн.: Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 200–13.
[Al'-Radi L.S. Volosatokletochnyi leikoz. V kn.: Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Ed. I.V. Poddubnoaya, V.G. Savchenko. 2018; p. 200–13 (in Russian).]
6. Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res 1980; 4 (6): 547–59.
7. Аль-Ради Л.С., Пивник А.В. Особенности течения и современная тактика терапии волосатоклеточного лейкоза. Клиническая онкогематология. 2009; 2 (1): 111–20.
[Al'-Radi L.S., Pivnik A.V. Osobennosti techeniia i sovremennaia taktika terapii volosatokletochnogo leikoza. Klinicheskaia onkogematologiia. 2009; 2 (1): 111–20 (in Russian).]
8. Matutes E et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma 1994; 14 (Suppl. 1): 57–61.
9. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16 (1): 41–56.
10. Аль-Ради Л.С. и др. Опыт изучения лимфомы красной пульпы селезенки. Терапевтический архив. 2016; 88 (4): 53–60.
[Al'-Radi L.S. et al. Opyt izucheniia limfomy krasnoi pul'py selezenki. Therapeutic Archive. 2016; 88 (4): 53–60 (in Russian).]
11. Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. Am J Hematol 2017; 92 (12): 1382–90.
12. Grever MR et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017; 129 (5): 553–60.
13. Robak T et al. Hairy Cell Leukaemia: ESMO Clinical Practice Guidelines. Ann Oncol 2015; 26 (Suppl. 5): v100–v107.
14. Maitre E, Cornet E, Troussard X. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol 2019; 94 (12): 1413–22.
15. Del Giudice I et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004; 89 (3): 303–8.
16. Tiacci E et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364 (24): 2305–15.
17. Arcaini L et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2012; 119 (1): 188–91.
18. Демина Е.А. и др. Общие принципы диагностики лимфом. В кн.: Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 9–27.
[Demina E.A. et al. Obshchie printsipy diagnostiki limfom. V kn.: Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 9–27 (in Russian).]
19. Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma 2011; 52 (Suppl. 2): 50–2.
20. Rai KR et al. Recombinant alpha-2β-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia 1995; 9 (7): 1116–20.
21. Federico M et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 1994; 5 (8): 725–31.
22. Falini B, Tiacci E. New treatment options in hairy cell leukemia with focus on BRAF inhibitors. Hematol Oncol 2019; 37 (S1): 30–7.
23. Dietrich S et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 2016; 127 (23): 2847–55.
24. Andrasiak I, Rybka J, Wrobel T. Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis. Clin Lymphoma Myeloma Leuk 2018; 18 (6): 392–9.e3.
25. Lauria F, Cencini E, Forconi F. Alternative methods of cladribine administration. Leuk Lymphoma 2011; 52 (Suppl. 2): 34–7.
26. Robak T et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: Final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007; 109 (9): 3672–5.
27. Else M et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145 (6): 733–40.
28. Zinzani PL et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer 2010; 116 (20): 4788–92.
29. Аль-Ради Л.С. и др. Лечение рецидивов волосатоклеточного лейкоза. Терапевтический архив. 2012; 84 (7): 4–9.
[Al'-Radi L.S. et al. Lechenie retsidivov volosatokletochnogo leikoza. Therapeutic Archive. 2012; 84 (7): 4–9 (in Russian).]
30. Chihara D et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 2016; 174 (5): 760–6.
31. Else M et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007; 110 (10): 2240–7.
32. Tiacci E et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 2015; 373 (18): 1733–47.
33. Burotto M et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res 2013; 19 (22): 6313–21.
34. Golomb HM, Hadad LJ. Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 1984; 16 (4): 393–401.
35. Siegal FP et al. Impaired interferon alpha response in hairy cell leukemia is corrected by therapy with 2-chloro-2’-deoxyadenosine: implications for susceptibility to opportunistic infections. Leukemia 1994; 8 (9): 1474–9.
36. Аль-Ради Л.С. и др. Туберкулез у больных лимфопролиферативными заболеваниями. Терапевтический архив. 2014; 86 (11): 42–9.
[Al'-Radi L.S. et al. Tuberkulez u bol'nykh limfoproliferativnymi zabolevaniiami. Therapeutic Archive. 2014; 86 (11): 42–9 (in Russian).]
37. Saven A et al. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999; 93 (8): 2471–7.
38. Aapro M. и др. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.
[Aapro M. et al. Klinicheskie rekomendatsii po lecheniiu anemii u bol'nykh zlokachestvennymi novoobrazovaniiami. M.: Assotsiatsiia onkologov Rossii, 2014 (in Russian).]
39. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016.
[Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I. Pirogova Minzdrava Rossii, 2016 (in Russian).]
40. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных. В кн.: Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 278–88.
[Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. V kn.: Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Ed. I.V.Poddubnaya, V.G.Savchenko. 2018; p. 278–88 (in Russian).]
41. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5; Suppl. 1): S88–94.
42. Аль-Ради Л.С. и др. Волосатоклеточный лейкоз и беременность. Терапевтический архив. 2017; 89 (7): 99–104.
[Al'-Radi L.S. et al. Volosatokletochnyi leikoz i beremennost'. Therapeutic Archive. 2017; 89 (7): 99–104 (in Russian).]
43. Al Bahar S, Pandita R, Nath SV. Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. Int J Gynaecol Obstet 2004; 85 (3): 281–2.
44. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.

________________________________________________

1. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, 2008.
2. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). Ed. S.H. Swerdlow, E. Campo, N.L. Harris et al. 2017.
3. Falini B, Martelli MP, Tiacci E. BRAF V600E mutation in hairy cell leukemia: From bench to bedside. Blood 2016; 128 (15): 1918–27.
4. Tadmor T, Polliack A. Epidemiology and environmental risk in hairy cell leukemia. Best Practice and Research: Clinical Haematology. Bailliere Tindall Ltd 2015; 28 (4): 175–9.
5. Al'-Radi L.S. Volosatokletochnyi leikoz. V kn.: Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Ed. I.V. Poddubnoaya, V.G. Savchenko. 2018; p. 200–13 (in Russian).
6. Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res 1980; 4 (6): 547–59.
7. Al'-Radi L.S., Pivnik A.V. Osobennosti techeniia i sovremennaia taktika terapii volosatokletochnogo leikoza. Klinicheskaia onkogematologiia. 2009; 2 (1): 111–20 (in Russian).
8. Matutes E et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma 1994; 14 (Suppl. 1): 57–61.
9. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16 (1): 41–56.
10. Аль-Ради Л.С. и др. Опыт изучения лимфомы красной пульпы селезенки. Терапевтический архив. 2016; 88 (4): 53–60.
[Al'-Radi L.S. et al. Opyt izucheniia limfomy krasnoi pul'py selezenki. Therapeutic Archive. 2016; 88 (4): 53–60 (in Russian).]
11. Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. Am J Hematol 2017; 92 (12): 1382–90.
12. Grever MR et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017; 129 (5): 553–60.
13. Robak T et al. Hairy Cell Leukaemia: ESMO Clinical Practice Guidelines. Ann Oncol 2015; 26 (Suppl. 5): v100–v107.
14. Maitre E, Cornet E, Troussard X. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol 2019; 94 (12): 1413–22.
15. Del Giudice I et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004; 89 (3): 303–8.
16. Tiacci E et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364 (24): 2305–15.
17. Arcaini L et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2012; 119 (1): 188–91.
18. Demina E.A. et al. Obshchie printsipy diagnostiki limfom. V kn.: Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 9–27 (in Russian).
19. Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma 2011; 52 (Suppl. 2): 50–2.
20. Rai KR et al. Recombinant alpha-2β-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia 1995; 9 (7): 1116–20.
21. Federico M et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 1994; 5 (8): 725–31.
22. Falini B, Tiacci E. New treatment options in hairy cell leukemia with focus on BRAF inhibitors. Hematol Oncol 2019; 37 (S1): 30–7.
23. Dietrich S et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 2016; 127 (23): 2847–55.
24. Andrasiak I, Rybka J, Wrobel T. Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis. Clin Lymphoma Myeloma Leuk 2018; 18 (6): 392–9.e3.
25. Lauria F, Cencini E, Forconi F. Alternative methods of cladribine administration. Leuk Lymphoma 2011; 52 (Suppl. 2): 34–7.
26. Robak T et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: Final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007; 109 (9): 3672–5.
27. Else M et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145 (6): 733–40.
28. Zinzani PL et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer 2010; 116 (20): 4788–92.
29. Al'-Radi L.S. et al. Lechenie retsidivov volosatokletochnogo leikoza. Therapeutic Archive. 2012; 84 (7): 4–9 (in Russian).
30. Chihara D et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol 2016; 174 (5): 760–6.
31. Else M et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007; 110 (10): 2240–7.
32. Tiacci E et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 2015; 373 (18): 1733–47.
33. Burotto M et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res 2013; 19 (22): 6313–21.
34. Golomb HM, Hadad LJ. Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 1984; 16 (4): 393–401.
35. Siegal FP et al. Impaired interferon alpha response in hairy cell leukemia is corrected by therapy with 2-chloro-2’-deoxyadenosine: implications for susceptibility to opportunistic infections. Leukemia 1994; 8 (9): 1474–9.
36. Al'-Radi L.S. et al. Tuberkulez u bol'nykh limfoproliferativnymi zabolevaniiami. Therapeutic Archive. 2014; 86 (11): 42–9 (in Russian).
37. Saven A et al. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999; 93 (8): 2471–7.
38. Aapro M. et al. Klinicheskie rekomendatsii po lecheniiu anemii u bol'nykh zlokachestvennymi novoobrazovaniiami. M.: Assotsiatsiia onkologov Rossii, 2014 (in Russian).
39. Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I. Pirogova Minzdrava Rossii, 2016 (in Russian).
40. Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. V kn.: Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Ed. I.V.Poddubnaya, V.G.Savchenko. 2018; p. 278–88 (in Russian).
41. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5; Suppl. 1): S88–94.
42. Al'-Radi L.S. et al. Volosatokletochnyi leikoz i beremennost'. Therapeutic Archive. 2017; 89 (7): 99–104 (in Russian).
43. Al Bahar S, Pandita R, Nath SV. Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. Int J Gynaecol Obstet 2004; 85 (3): 281–2.
44. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.

Л.С. Аль-Ради1, В.В. Байков2, А.М. Ковригина1,3, Ю.А. Криволапов4, Т.Н. Моисеева1, Е.А. Никитин5,6, А.В. Пивник7, Е.А. Стадник2,8, А.А. Невольских9, С.А. Иванов9, Ж.В. Хайлова9, Т.Г. Геворкян10

1 ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия;
2 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия;
3 ФГБОУ ДПО «Институт повышения квалификации» ФМБА России, Москва, Россия;
4 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, 
Санкт-Петербург, Россия;
5 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
6 ГБУЗ «Городская клиническая больница им. С.П. Боткина» Департамента здравоохранения г. Москвы, Москва, Россия;
7 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия;
8 ФГБУ «Северо-Западный федеральный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России, 
Санкт-Петербург, Россия;
9 Медицинский радиологический научный центр им. А.Ф.Цыба – филиал ФГБУ «Научный медицинский исследовательский центр радиологии» Минздрава России, Обнинск, Россия;
10 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия

________________________________________________

Liubov S. Al'-Radi1, Vadim V. Baikov2, Alla M. Kovrigina1,3, Iurii A. Krivolapov4, Tatiana N. Moiseeva1, Evgenii A. Nikitin5,6, Aleksandr V. Pivnik7, Elena A. Stadnik2,8, Aleksei A. Nevol'skikh9, Sergei A. Ivanov9, Zhanna V. Khailova9, Tigran G. Gevorkian10

1 National Medical Research Center of Hematology, Ministry of Health of Russia, Moscow, Russia;
2 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
3 Institute for Advanced Studies, Moscow, Russia;
4 Mechnikov North-West State Medical University, Saint Petersburg, Russia;
5 Russian Medical Academy of Continuing Professional Education, Moscow, Russia;
6 Botkin City Clinical Hospital, Moscow, Russia;
7 Loginov Moscow Clinical Scientific and Practical Center, Moscow, Russia;
8 Almazov North-West Federal Medical Research Center, Saint Petersburg, Russia;
9 Tsyb Medical Radiological Scientific Center – branch of Scientific Medical Research Center of Radiology, Obninsk, Russia;
10 Blokhin National Medical Research Center of Oncology, Moscow, Russia